Loading stock data…
APYX
$3.92+0.25 (+6.81%)
Market ClosedLast close May 11
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apyx Medical Corporation in the Healthcare sector is trading at $3.92. The stock is currently near its 52-week high of $4.50, remaining 20.6% above its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why APYX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.92
Potential Upside
5%
Whystock Fair Value$4.12
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$160.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-131.62%
Volume
Today's trading volume
418,563
Recent News
Apyx Medical Corporation (NASDAQ:APYX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.50
As you might know, Apyx Medical Corporation ( NASDAQ:APYX ) just kicked off its latest first-quarter results with some...
Apyx Medical (APYX) Q1 2026 Earnings Transcript
Charles Goodwin: Thank you, Jeremy, and thank you all for joining us today. This growth was driven by a 36% increase in sales of our Surgical Aesthetics products to $10.7 million for the first quarter, which was primarily attributable to the continued strong sales ramp of our AYON body contouring system in the U.S., demand for single-use handpieces worldwide and increase in Renuvion generator sales internationally. This represents our second full quarter of AYON sales following its full commercial launch in September 2025.
NewBeauty Award Win Keeps Attention on Apyx Medical’s Renuvion Growth Strategy
Apyx Medical highlighted another industry recognition for Renuvion as the company continues expanding its minimally invasive body contouring platform. Key Investor TakeawaysApyx Medical (NASDAQ:APYX) said Renuvion received the 2026 NewBeauty Award for “Best Minimally Invasive Skin Tightener” for the second straight year.
Apyx Medical Q1 Earnings Call Highlights
Apyx Medical (NASDAQ:APYX) reported first quarter 2026 revenue of $12.5 million, up from $9.4 million in the prior-year period, driven primarily by growth in its Surgical Aesthetics business and continued momentum from the company’s AYON body contouring system, which launched commercially in Septemb
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
Apyx (APYX) delivered earnings and revenue surprises of +54.55% and +6.23%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?